Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q96JD6

UPID:
AKCL2_HUMAN

ALTERNATIVE NAMES:
Aldo-keto reductase family 1 member C-like protein 2; Aldo-keto reductase family 1 member E2; LoopADR; Testis aldo-keto reductase; Testis-specific protein

ALTERNATIVE UPACC:
Q96JD6; Q86Z16; Q86Z17; Q86Z18; Q9BU71

BACKGROUND:
The enzyme 1,5-anhydro-D-fructose reductase, also referred to as Aldo-keto reductase family 1 member E2 and LoopADR, is integral to the conversion of 1,5-anhydro-D-fructose into 1,5-anhydro-D-glucitol. Its activity is essential for the proper functioning of carbohydrate metabolism, supported by its ability to utilize NADPH for the reduction of specific substrates. The protein's low NADPH-dependent reductase activity towards compounds like 9,10-phenanthrenequinone further demonstrates its biochemical significance.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of 1,5-anhydro-D-fructose reductase offers a promising avenue for the development of novel therapeutic approaches. As a key player in metabolic processes, targeting this enzyme could lead to breakthroughs in the treatment of diseases related to carbohydrate metabolism and energy regulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.